0RA9.L
Price:
$5.28
Market Cap:
$325.43M
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengu...[Read more]
Industry
Medical - Pharmaceuticals
IPO Date
2016-09-30
Stock Exchange
LSE
Ticker
0RA9.L
According to ABIVAX SA’s latest financial reports and current stock price. The company's current PE Ratio is -2.14. This represents a change of 12.92% compared to the average of -1.90 of the last 4 quarters.
The mean historical PE Ratio of ABIVAX SA over the last ten years is -6.89. The current -2.14 PE Ratio has changed 3.01% with respect to the historical average. Over the past ten years (40 quarters), 0RA9.L's PE Ratio was at its highest in in the June 2014 quarter at 0. The PE Ratio was at its lowest in in the June 2015 quarter at -6.81.
Average
-6.89
Median
-7.60
Minimum
-13.11
Maximum
-1.97
Discovering the peaks and valleys of ABIVAX SA PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 47.65%
Maximum Annual PE Ratio = -1.97
Minimum Annual Increase = -82.94%
Minimum Annual PE Ratio = -13.11
Year | PE Ratio | Change |
---|---|---|
2024 | -2.42 | -15.52% |
2023 | -2.86 | 45.07% |
2022 | -1.97 | -82.94% |
2021 | -11.57 | -11.75% |
2020 | -13.11 | 46.17% |
2019 | -8.97 | 17.77% |
2018 | -7.61 | 0.31% |
2017 | -7.59 | 78.60% |
2016 | -4.25 | -50.36% |
2015 | -8.56 | 47.65% |
The current PE Ratio of ABIVAX SA (0RA9.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.42
5-year avg
-6.39
10-year avg
-6.89
ABIVAX SA’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ABIVAX SA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ABIVAX SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ABIVAX SA's PE Ratio?
How is the PE Ratio calculated for ABIVAX SA (0RA9.L)?
What is the highest PE Ratio for ABIVAX SA (0RA9.L)?
What is the 3-year average PE Ratio for ABIVAX SA (0RA9.L)?
What is the 5-year average PE Ratio for ABIVAX SA (0RA9.L)?
How does the current PE Ratio for ABIVAX SA (0RA9.L) compare to its historical average?